Weight Loss

New research shows that losing fat the wrong way can disrupt metabolism, trigger inflammation, and increase long-term disease risk, challenging the idea that less fat is always better

From bridal skincare to fitness makeovers, India’s pre-wedding industry is evolving fast. Now, weight-loss injections like Mounjaro are becoming part of that transformation, raising questions about he

Doctors caution against cosmetic misuse of GLP-1 drugs as cheaper generics boost access, raising risks of unsupervised use and short-term weight-loss trends

Mounjaro sales in March dropped to ₹114 crore ($12.3 million) in March from ₹135 crore a month earlier, Pharmarack data show

Experts explain the science behind hair loss reports, noting that the shedding is usually temporary and linked to how the body responds to rapid weight loss

Regulators have been asked to track adverse events as India tightens oversight on popular obesity drugs amid rising demand and concerns over misuse and misleading promotions

Many marriages are still arranged by families, often accompanied by expectations around physical appearance and financial status, which is driving a growing demand for weight-loss solutions

Cheap, accessible, and powerful semaglutide is changing India’s weight-loss and diabetes landscape. But as prices crash and access expands, the risks also increase

A week before semaglutide's patent expiry, the CDSCO issued an advisory warning pharma companies against promoting prescription weight-loss drugs, banned by law

Online pharmacies, drug wholesalers under scanner; non-compliance may lead penalties, license cancellations

Experts highlight the limits of calorie tracking and share practical, sustainable ways for long-term weight management

India's 'cheap Ozempic moment' is here as semaglutide prices fall sharply, but doctors warn against misuse and stress careful evaluation before using these weight-loss injections

As cheaper GLP-1 weight-loss drugs flood India after patent expiry, the government has intensified surveillance to curb illegal sales, misleading promotion, and unsafe use without medical supervision

To ensure ethical pharmaceutical practices in the supply chain of weight-loss drugs of the GLP-1 class, the Drugs Controller General of India (DCGI) has intensified its regulatory surveillance against the unauthorised sale and promotion of the medications. To this end, inspections and audits have been carried out at many online pharmacy warehouses, drug wholesalers and retailers to check for unauthorised sale and improper prescription. With the recent introduction of multiple generic variants of GLP-1-based weight-loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics, health ministry officials said on Tuesday. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks. Taking cognisance of the situation, the DCGI, in collaboration with state regulators, has initiated a series of targeted actions to curb .

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

As semaglutide goes off patent, doctors warn of misuse by non-obese individuals amid rising demand driven by social media and lower-cost generics

Natco Pharma Ltd. plans to sell an injection for semaglutide, the active ingredient in both Ozempic and Wegovy - with prices starting from ₹1,290

India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions

India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions

Body weight is biologically regulated, and targeting the right biological pathways can lead to meaningful weight loss that can help transform lives